At the American Society of Human Genetics (ASHG) 2025 industry session, Oxford Nanopore Technologies announced a series of major updates aimed at advancing translational and clinical human genetics. The company’s new developments are designed to help researchers and clinicians achieve…
ClearB Therapeutics, Inc., a clinical-stage biotechnology company dedicated to developing therapies aimed at achieving functional cure in patients with chronic hepatitis B (CHB) infection, announced that the sentinel subject safety review in their ongoing Phase 1b study of CLB-4000 supports…
PeptiDream Inc., PDRadiopharma Inc. — a wholly owned subsidiary of PeptiDream — and Curium Group, a global leader in nuclear medicine, have announced the initiation of a registrational Phase 2 clinical trial in Japan for 64Cu-PSMA-I&T, a novel PET radiopharmaceutical…
Eradivir Inc., a clinical-stage biotechnology company leveraging the immune system to treat infectious diseases, today announced the successful completion of its Phase 2a clinical trial evaluating EV25, a novel therapy for influenza. The trial demonstrated that EV25 is safe, well-tolerated,…
Eikon Therapeutics, Inc., a late-stage clinical biopharmaceutical company focused on integrating advanced engineering with cutting-edge laboratory and in silico research to accelerate drug discovery, today announced that new data from its ongoing Phase 2 study of EIK1001 (TeLuRide-005) will be…
Augurex Life Sciences Corp., a leading innovator in autoimmune-based diagnostics, today announced a strategic agreement with MitogenDx, a Canadian specialty laboratory focused on autoimmune and rheumatology diagnostic testing. Under the terms of the agreement, MitogenDx will offer the JOINTstat® blood…
ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer and Shionogi as shareholders, announced new data from the phase I CLARITY open-label crossover study, highlighting significant differences in injection site reaction (ISR) acceptability and overall tolerability between…
Echo, a global leader in hydrogen wellness technology, has highlighted new research that strengthens the case for molecular hydrogen (H₂) as a powerful aid in lung recovery and inflammation reduction following high-intensity exercise. The study, recently published in the Journal…
Oticara, a clinical-stage pharmaceutical company focused on developing innovative therapies for chronic rhinosinusitis (CRS), announced encouraging results from its Phase 2 OT-007B clinical trial. The study evaluated Oticara’s proprietary nasal-mucosa-optimized steroid cream in patients suffering from persistent CRS symptoms after…
Alzheon, Inc., a clinical-stage biopharmaceutical company advancing novel therapies and diagnostics for Alzheimer’s disease (AD) and other neurodegenerative disorders, announced the peer-reviewed publication of its pivotal APOLLOE4 Phase 3 trial results in Drugs, a leading scientific journal. The paper, titled…